Market Research Report
Global Allergic Rhinitis Drugs Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||759917|
|Published||Content info||113 Pages
Delivery time: 1-2 business days
|Global Allergic Rhinitis Drugs Market 2019-2023|
|Published: December 7, 2018||Content info: 113 Pages||
The rise in R&D of new therapies is expected to drive growth in the market. There has been an increase in the prevalence of allergic diseases globally. If these diseases are not managed at an early stage, allergic diseases such as rhinitis can increase the risk of asthma in patients. Several organizations are trying to understand the pathogenesis of these diseases. Technavio's analysts have predicted that the allergic rhinitis drugs market will register a CAGR of close to 4% by 2023.
The increase in the prevalence of allergic rhinitis is expected to increase the pool of patients as well as the consumption of medicine. This worldwide increase in the incidence of allergic rhinitis is likely to drive growth of the allergic rhinitis drugs market.
The increase in competition from generics is expected to adversely affect the market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the allergic rhinitis drugs market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Sanofi and Stallergenes Greer the competitive environment is quite intense. Factors such as the increase in the prevalence of allergic rhinitis and the rise in R&D of new therapies, will provide considerable growth opportunities to allergic rhinitis drugs manufactures. ALK-Abello, GlaxoSmithKline, Merck, Sanofi, and Stallergenes Greer are some of the major companies covered in this report.